Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SCN4A | P35499 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | PKM | P14618 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31068436 | 0.88 | HTR6 (0.41) | HTR6HTR2ATSHRLMNAMAPK1 | |
| SCHEMBL31147849 | 0.86 | HTR6 (0.40) | HTR6HTR2ATSHRLMNAMAPK1 | |
| SCHEMBL3246036 | 0.85 | ATM (0.40) | HTR6HTR2ATSHRLMNAMAPK1 | |
| Hydrochloric Acid SCHEMBL28109987 | 0.83 | ATM (0.39) | HTR6HTR2ATSHRLMNAMAPK1 | |
| SCHEMBL17183712 | 0.82 | HTR2A (0.35) | HTR6HTR2ATSHRLMNAMAPK1 | |
| SCHEMBL9309445 | 0.80 | HTR2A (0.38) | HTR6HTR2ATSHRLMNAMAPK1 | |
| SCHEMBL29401941 | 0.79 | EDNRA (0.39) | HTR6HTR2ATSHRMAPK1ATM | |
| SCHEMBL63928 | 0.79 | EDNRA (0.39) | HTR6HTR2ATSHRMAPK1ATM | |
| SCHEMBL3609519 | 0.79 | HTR2A (0.36) | HTR6HTR2ATSHRLMNAMAPK1 | |
| SCHEMBL27970744 | 0.78 | HTR2A (0.37) | HTR6HTR2ATSHRLMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1011670-A4 | METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS | LILLY CO ELI (US) | 2004-10-27 | — | — | EP | claimed |
| JP-2003525901-A | — | — | 2003-09-02 | — | — | JP | claimed |
| US-20030119860-A1 | METHOD FOR TRATMENT OF NON-RHEUMATOID ARTHRITIS | ELI LILLY AND COMPANY | 2003-06-26 | — | — | US | claimed |
| US-20030087944-A1 | Method for the treatment of renal dysfunction with spla2 inhibitors | CONCORD (HK) INTERNATIONAL EDUCATION LIMITED (HK) | 2003-05-08 | — | — | US | claimed |
| EP-1265607-A2 | METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA 2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-12-18 | — | — | EP | claimed |
| WO-2001066111-A1 | COMPOSITIONS CONTAINING POTENTIAL SPLA2 INHIBITORS FOR THE TREATMENT OF PAIN | ELI LILLY AND COMPANY (US) | 2001-09-13 | — | — | WO | claimed |
| WO-2001066110-A2 | METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-09-13 | — | — | WO | claimed |
| WO-2001055108-A2 | USE OF SPL A2 INHIBITORS FOR THE TREATMENT OF INFLAMMATION | ELI LILLY AND COMPANY (US) | 2001-08-02 | — | — | WO | claimed |
| EP-1011670-A1 | METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS | ELI LILLY AND COMPANY (US) | 2000-06-28 | — | — | EP | claimed |
| EP-1007056-A1 | METHOD FOR THE TREATMENT OF CYSTIC FIBROSIS | ELI LILLY AND COMPANY (US) | 2000-06-14 | — | — | EP | claimed |
| WO-1999016453-A1 | METHOD FOR THE TREATMENT OF CYSTIC FIBROSIS | ELI LILLY AND COMPANY (US) | 1999-04-08 | — | — | WO | claimed |
| WO-1999009978-A1 | METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS | ELI LILLY AND COMPANY (US) | 1999-03-04 | — | — | WO | claimed |
| EP-0769940-A4 | — | — | 1997-06-11 | — | — | EP | claimed |
| EP-0769940-A1 | INDENE sPLA 2? INHIBITORS | ELI LILLY AND COMPANY (US) | 1997-05-02 | — | — | EP | claimed |
| WO-1996003120-A1 | INDENE sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1996-02-08 | — | — | WO | claimed |
| EP-1011670-A4 | METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS | LILLY CO ELI (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20040110825-A1 | Administration of an enzyme inhibitor of human non-pancreatic scretory phospholipase A2 (sPLA2) if activity levels are high or on the rise; treating within 0-24 hours after first organ failure and continuing as necessary, i.e., 1-7 days | LOH ANDREW (US) | 2004-06-10 | — | — | US | disclosed |
| EP-0769940-A1 | INDENE sPLA 2? INHIBITORS | ELI LILLY AND COMPANY (US) | 1997-05-02 | — | — | EP | disclosed |
| WO-1996003120-A1 | INDENE sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1996-02-08 | — | — | WO | disclosed |
| WO-1996003120-A1 | INDENE sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110825-A1 | Administration of an enzyme inhibitor of human non-pancreatic scretory phospholipase A2 (sPLA2) if activity levels are high or on the rise; treating within 0-24 hours after first organ failure and continuing as necessary, i.e., 1-7 days | PLA2G12A, PLA2G2E, PLA2G3 | HTR6 3251/4885HTR2A 1210/4885TSHR 4438/4885 |
| US-20030087944-A1 | Method for the treatment of renal dysfunction with spla2 inhibitors | IDO2, SPINT2, IDO1 | HTR6 341/4885HTR2A 35/4885TSHR 4056/4885 |
| US-20030119860-A1 | METHOD FOR TRATMENT OF NON-RHEUMATOID ARTHRITIS | TPP2, PLAAT2, PLAA | HTR6 1473/4885HTR2A 555/4885TSHR 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.